Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Bullboard Posts
Comment by spike55on Feb 21, 2020 4:34pm
74 Views
Post# 30719491

RE:RE:RE:RE:RE:RE:RE:RE:5 to 7 dollars a share!!!!

RE:RE:RE:RE:RE:RE:RE:RE:5 to 7 dollars a share!!!!In other words you know nothing.....once the quarterly results come out and cash builds on the balance sheet the stock will rise, until then the market feels it is too risky and the company is not good at deploying Capital.

Right now the market is saying they are not convinced with Absorica LD. 




pabaloo wrote: You are correct I wouldn't be asking. No where has anyone thrown out a number to my knowledge. Watch analysts from bnn most are scum bags that drop may could should which means sweet F A. I don't even know if he's done as much research as I have. I spent the past 3 months researching everything I could find on Ciphr and made spread sheets to trend earnings revenue and costs. Half my sheets are empty or filled in with guesses. That's why real analyst take a pass on this stock there are no zero tangibles to figure out where they are going only where they have been and it's not pretty. If there is no sale of assets or the company we are stuck in this trend around a dollar. Everyone now knows the deal with Sun they know revenue will be up and profits for the next 2 years and still zero up trend. Puzzling at best.


Bullboard Posts